Lymphoma – What’s New?
1.0 CE Credit Hour / Philip Bergman, DVM, MS, PhD, DACVIM
Philip Bergman, DVM, MS, PhD, DACVIM
Dr. Bergman is the Director of Clinical Studies for Mars Veterinary Health. He is the principal veterinary investigator for the fully licensed canine melanoma vaccine (Oncept). Dr. Bergman is an adjunct faculty member of the Memorial Sloan-Kettering Cancer Center. Prior to Dr. Bergman joining VCA, he served as the Chief Medical Officer for BrightHeart Veterinary Centers from July 2007 to August 2011; from 1999 to June 2007 he was the head of the Donaldson-Atwood Cancer Center at AMC. After finishing veterinary school from Colorado State in 1990, he was an intern at Kansas State (90-91) and returned to CSU for his medical oncology residency (91-94) and then completed a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (94-99). He was previously Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society. Dr. Bergman has been an veterinary oncologist at Katonah Bedford Veterinary Center since 2007.
Overview:
Lymphoma is the most common tumor of the cat, and one of the most common tumors in the dog. The diagnostic, prognostic and therapeutic approach to this tumor will be discussed. Particular emphasis will be placed on the various treatment protocols available, as well as options for rescue chemotherapy in dogs and cats.
Learning Objectives:
- Better understand the diagnostic landscape for dogs and cats with lymphoma
- Review the literature for the best diagnostic applications to determine immunophenotype
- Become more fluent in typical outcomes for dogs and cats treated with various protocols for lymphoma
- Better understand some of the new diagnoses for low grade GI lymphoma in cats
This course is RACE-approved for 1.0 continuing education credits hours in jurisdictions that accept RACE-approval.
This activity is sponsored by Volition Veterinary.
